Read our insightful science articles
See Clinical Studies
How data science helps us part with traditional thinking
Data science has the potential to revolutionize our industry, and as an early adopter, it plays a central role in our innovation and development process.
At Novozymes OneHealth, we apply Data Science in diverse areas, such as the extraction of insights from consumer data, text-mining of scientific publications, and in the data mining of large clinical datasets. These activities are driven by a combination of state-of-the-art computational tools and AI-based methods.
A significant focus area is what we call “Human-First Discovery”. In this approach, we learn directly from real-world clinical data (human-first) to help to maintain health in areas of interest to us or our partners. This gives us a direct view on how the microbiome and other variables impact the human host in different phenotypes and is a perfect complement to the classical probiotic screening process known to the industry.
Our work is focused on building AI-powered predictive models that are continuously trained on new data. This is a completely new approach within the industry and allows us to identify new probiotic leads and biomarkers, increase the efficiency of clinical trials, understand modes of action, and much more. We can bring human context to our vast strain and enzyme libraries even before doing clinical trials, which greatly decreases lead-generation time.
Our data assets and AI-based discovery platform fuel our innovation efforts both internally and through strategic innovation partnerships.
‘No black boxes’ and ‘no flagship strain’ philosophy
Transparency is our guiding light. Once we identify the mode of action needed to deliver a specific health benefit, we are then able to select the best probiotic, enzyme, or combination of bioactives to meet the task at hand. We develop, iterate, and then we conduct pre-clinical and clinical studies with the solution to prove it works and to document its mode of action. We are committed to explaining a clear, transparent mode of action for every One-in-a-trillion solution we develop.
We’re never attempting to validate a solution’s efficacy so as to confer as many health benefits as possible, nor do we need to try and reverse engineer any processes. We purpose-build our solutions to address a specific health benefit.
Our ethics and quality controls
All pre-clinical and clinical work is approved by our Scientific Ethics Committees. We also consult field experts to attain appropriate study designs, and consider regulatory requirements and statistical plans to ensure proven solutions meet the highest standards.
Before going ahead, all trial data and plans are presented to an advisory board. These world-renowned, subject-matter experts represent a breadth of knowledge capacities and expertise to ensure the trial is of quality and is responsible from all angles.
The Novozymes OneHealth Innovation Cluster
We also develop and maintain world-class partnerships with key opinion leaders in their specialty fields to enhance our access to the best scientific innovation and thought leadership. This includes strong academic partners. In Denmark, we partner with the Danish Technical University, the BioInnovation Institute, the University of Copenhagen, and the University of Aarhus. In the United States, we have strong relationships with the University of California group and its 10 campuses.
OneHealth is building two Centers of Innovation Excellence: One in Denmark and one in California. We’re building true partnerships where we co-create our pipeline, meaning we can really bring the best from science in academia and innovation to consumers.
Have questions about our One-in-a-trillion solutions? Please reach out!
We're here to help you.